Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,409 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT05276310RecruitingPhase 1
Study of IMC-002 in advanced cancer
This study tests a new drug called IMC-002 in people with advanced cancer that has not responded to standard treatment. It aims to see if the drug is safe and effective, and may be given alone or with other treatments depending on the cancer type.
Goyang-siAges 19 years+ - NCT05287126RecruitingPhase 2
Etrasimod for teens with active ulcerative colitis
This trial tests whether etrasimod can improve ulcerative colitis (UC) symptoms in adolescents with moderate to severe, active disease. It may help reduce inflammation and disease activity, especially if current treatments aren’t working well enough.
Little Rock, ArkansasAges 12–17 - NCT05304377RecruitingPhase 1
Early trial drug for chronic-phase CML after prior treatments
This Phase 1 study tests ELVN-001 in people with chronic-phase chronic myeloid leukemia (CML) who have had limited benefit or side effects from other CML medicines. It may help shrink leukemia activity safely and find the best dosing for people who still need treatment options.
New York, New YorkAges 18 years+ - NCT05304962RecruitingPhase 1
Test drug RGT-419B for advanced ER+ HER2- breast cancer
This Phase 1 study tests a new drug (RGT-419B), given alone or with hormone (endocrine) therapy, in people with advanced ER-positive, HER2-negative breast cancer that has progressed after standard treatments. It looks mainly at safety and early signs of how well the treatment may work.
La Jolla, CaliforniaAges 18 years+ - NCT05306132RecruitingPhase 1
Test drug ASKC202 for advanced lung cancer and MET-positive tumors
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
Zhengzhou, HenanAges 18 years+ - NCT05276726RecruitingPhase 1/Phase 2
Test drug JAB-21822 for KRAS G12C NSCLC with STK11
This trial studies how well the drug JAB-21822 works in people with advanced or spread lung cancer (NSCLC) that has a specific genetic change: KRAS G12C, plus STK11 and no KEAP1 change. It’s designed to see safety and early signs of effectiveness, especially if you haven’t been treated much yet.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05257993RecruitingPhase 1/Phase 2
Pancreatic cancer trial testing JPI-547 with standard chemo
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
Gyeonggi-doAges 19–79 - NCT05265273RecruitingPhase 2/Phase 3
Nipocalimab for children with generalized myasthenia gravis
This trial studies nipocalimab, an immune-focused medicine, to see if it can improve generalized myasthenia gravis (gMG) in children ages 2 to under 18. It may help reduce weakness caused by this autoimmune muscle disease, but you must meet specific antibody and health requirements.
Phoenix, ArizonaAges 2–17 - NCT05303064RecruitingPhase 3
Study of weight gain medicine for teens with certain mood or psychosis
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
Dothan, AlabamaAges 10–17 - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT02841553Recruiting
Online registry for Wolfram syndrome worldwide
This study builds an international online registry to learn how Wolfram syndrome (and related WFS1 conditions) changes over time. It may help researchers understand the disease course and improve future care by collecting health and family history data.
St Louis, MissouriAges birth+ - NCT04245397RecruitingPhase 1
Test drug SX-682 with decitabine for myelodysplastic syndrome
This Phase 1 trial tests whether SX-682 given alone or with decitabine can treat myelodysplastic syndrome (MDS) that has not responded well to prior therapy. It also studies safety and the best dose, which may help people who have limited treatment options.
Jacksonville, FloridaAges 18 years+ - NCT04179695Recruiting
Testing a new communication aid to improve patient-centered care
This study tests a new tool meant to help patients and healthcare teams communicate better and support “patient-centered care.” You may be invited to use the tool and complete study activities during your neurology care visits.
LilleAges 18–90 - NCT05105152RecruitingPhase 1
CAR T cell therapy for kids with CD33 AML that came back
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
Seattle, WashingtonAges Up to 30 years - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
La Jolla, CaliforniaAges 18 years+ - NCT05238740Recruiting
Compare fusion results after two spine surgeries with added biologics
This study compares two types of spine surgery (ALIF or XLIF) for one spinal level, and tests how well the bones fuse when a specific bone-forming product is used. It also looks at how patients feel and function after surgery.
BernAges 18–70 - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT05199688RecruitingPhase 3
Satralizumab for children with AQP4-positive NMOSD attacks
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Denver, ColoradoAges 2–11 - NCT05230745Recruiting
Test device for heart failure safety and how well it works
This trial studies whether the ContraBand device can be safely placed in people with long-term, symptomatic heart failure and reduced heart pumping. It also looks at whether the approach is practical and tolerable, and gathers early safety information.
AalstAges 18–85 - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Glendale, ArizonaAges 18 years+ - NCT05245695Recruiting
Endometriosis test using deep computer learning during surgery
This trial studies whether a computer (deep neural network) can better identify endometriosis in people with long-lasting pelvic pain using information from surgery. It may help doctors sort who has endometriosis more accurately when surgery is already planned.
Chandler, ArizonaAges 14–50
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,409 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.